Cannabis-related side effects: Key findings
Key findings regarding cannabis-related side effects in Canada.
- Last updated: ...
During the reporting period (2018 to 2024), ... cases of side effects involving legal cannabis products were reported to Health Canada. We analyzed these cases and summarized the key findings on this page.
Throughout this dashboard:
- Side effects are also referred to as adverse reactions. They're defined as “noxious and unintended response to a cannabis product” in the Cannabis Regulations. See Understanding the data for other definitions.
- The reporting period refers to October 17, 2018 to December 31, 2024.
On this page
- Summary of side effects cases
- Serious side effects and reason for cannabis use
- Side effects reported by age and sex
- Types of cannabis products involved
- Outcomes
- Learn more
Summary of cases submitted between October 17, 2018 and December 31, 2024
Serious side effects and reason for cannabis use
- Most side effects were reported as serious. There was a significant increase in the proportion of serious cases between 2018-2019 and 2020, followed by variability thereafter (i.e., significant increase in 2021, significant increase in 2022, significant decrease in 2023 and a non-significant decrease in 2024).
- The most common reason selected for seriousness was ‘Other - medically important condition’ for all years except 2018-2019, when ‘hospitalisation’ was the most common reason (data not shown).
- Most cases involved the use of cannabis for self-reported medical purposes. However, there was a significant decrease in the proportion of these cases between 2018-2019 and 2021. While the proportion of cases involving self-reported use of cannabis for medical purposes was variable in 2022 (decrease), 2023 (increase) and 2024 (decrease), this variability was not significant.
Figure 1. of cases submitted to Health Canada over time by ,
Figure 1: Notes
- For definitions, see the Understanding the data tab.
- Seriousness is based on the initial report and may change if more information is submitted to Health Canada.
Figure 1: Text description
Note: use the "Filter items" search bar below to filter the table for information of interest. For example, to view data related only to the most recent year for which data is available, type ‘2023’ in the search bar.
- A period (".") indicates that statistical significance was not calculated (when it appears in the "Significant difference from previous year" column) or that data was suppressed due to a low count (when it appears in the "Number" column).
- A hyphen ("-") indicates that no previous year was available for comparison to the relevant row, so no significant difference from previous year could be calculated.
Side effects reported by age and sex
- Side effects were more frequently reported for females than males in all years except 2022 and 2024. However, there was a significant decrease in the proportion of cases involving females from 2020 to 2022, with a significant increase in the proportion in 2023. The decline in female proportion of cases from 2023 to 2024 was not significant.
- Where age was reported, side effects were most frequently reported among people aged 18 to 44, except for 2021 and 2024 where 45 to 64 years was the most frequently involved age group. However, the number of cases without age reported continues to be large.
Figure 2. of cases submitted to Health Canada over time
Figure 2: Notes
- If the year of birth and the date of reaction are listed in the report, the age is calculated.
- If the year of birth is listed without a date of reaction, the report date is used to calculate the age.
- Age groupings are aligned with the World Health Organization's Vigilyze database (Vigibase) categories.
Figure 2: Text description
Note: use the "Filter items" search bar below to filter the table for information of interest. For example, to view data related only to the most recent year for which data is available, type ‘2023’ in the search bar.
- A period (".") indicates that statistical significance was not calculated (when it appears in the "Significant difference from previous year" column) or that data was suppressed due to a low count (when it appears in the "Number" column).
- A hyphen ("-") indicates that no previous year was available for comparison to the relevant row, so no significant difference from previous year could be calculated.
Types of cannabis products involved
- Cannabis extracts, such as oils, capsules, sprays, and vaping liquids, were the most common product class reported each year, followed by dried cannabis. However, the proportion of cases involving extracts and dried cannabis has declined overall, while the proportion involving edible cannabis has increased over time. Likewise, the proportion of cases involving multiple cannabis products from different product classes has increased over time.
- Some classes of cannabis (edible cannabis, topicals, and extracts other than ingestible oils) weren’t legally available to Canadian consumers until October 17, 2019. This was when Phase II of the legalization and regulation of cannabis for non-medical purposes began, legalizing edible cannabis, beverages, extracts, and topicals. However, these products were not available for retail sale until January, 2020.
Figure 3. of cases submitted to Health Canada over time ,
Figure 3: Notes
- Cases may involve multiple suspected cannabis products and different classes of cannabis product.
- Cannabis extracts as a class include a diverse group
of product forms including:
- oral liquids/drops
- softgels
- capsules/tablets
- sublingual sprays
- dissolvable strips
- highly concentrated extracts like shatter, wax, rosin, resin, or vaping liquids
- Dried cannabis includes:
- whole dried flower
- milled flower
- pre-rolls
- Edible cannabis includes:
- foods such as chocolate, confectionary, and mints
- beverages
Figure 3: Text description
Note: use the "Filter items" search bar below to filter the table for information of interest. For example, to view data related only to the most recent year for which data is available, type ‘2023’ in the search bar.
- A period (".") indicates that statistical significance was not calculated (when it appears in the "Significant difference from previous year" column) or that data was suppressed due to a low count (when it appears in the "Number" column).
- A hyphen ("-") indicates that no previous year was available for comparison to the relevant row, so no significant difference from previous year could be calculated.
Outcomes
- Most of the reported adverse events involved psychiatric disorders, followed by nervous system disorders, general disorders and administration site conditions, gastrointestinal disorders, and respiratory, thoracic and mediastinal disorders. These top classes were generally consistent across all years but in varying order.
- The most commonly reported side effect in 2018-2019, 2020, and 2021 was hallucination, while headache was the most commonly reported side effect in 2022 and 2023, and dyspnea in 2024.
Figure 4. Number of times particular
were reported in
cannabis side effect cases over time
Showing ... of ...
Select a system organ class on the vertical axis to explore data on the preferred terms relating to that system organ class. Click any preferred term to return to the original system organ class view.
Figure 4: Notes
- Events are coded according to MedDRA based on the information in the case report. MedDRA provides standardized medical terminology in hierarchical groupings. The highest-level grouping is the System Organ Class (SOC) and the lowest level is the Preferred Term (PT).
- Each case may describe 1 or more medical events and associated signs, symptoms, diseases, diagnoses, investigations, and procedures.
- One side effect case may be represented across multiple SOCs, and is influenced by how individual events (signs, symptoms, observations, or diagnostics) are reported.
- Each case can have multiple individual events reported, so the number of individual events exceeds the total number of cases.
- Several types of hallucination were combined to create an all-inclusive hallucination category. These included auditory hallucination, visual hallucination, mixed hallucination, hypnagogic hallucination, and pseudohallucination.
- The inclusion of a particular report in the database does not necessarily mean that the suspected product caused it. Further scientific investigation is needed to establish a cause-and-effect relationship between a cannabis product and a side effect.
Figure 4: Text description
Note: use the "Filter items" search bar below to filter the table for information of interest. For example, to view data related only to the most recent year for which data is available, type ‘2023’ in the search bar.
- A period (".") indicates that statistical significance was not calculated (when it appears in the "Significant difference from previous year" column) or that data was suppressed due to a low count (when it appears in the "Number" column).
- A hyphen ("-") indicates that no previous year was available for comparison to the relevant row, so no significant difference from previous year could be calculated.
We’ll continue to monitor these trends and investigate any longer-term impacts of legalizing and regulating cannabis in Canada. We’ll also continue to publish these data and use them to help inform educational and outreach resources for consumers and healthcare professionals.
Learn more
Read the full reports
- Data on cannabis adverse reactions 2018 to 2019: Annual report - Canada.ca
- Data on cannabis adverse reactions: 2020 annual report - Canada.ca
- Data on cannabis adverse reactions: 2021 annual report - Canada.ca
- Data on cannabis adverse reactions: 2022 annual report - Canada.ca
- Data on cannabis adverse reactions: 2023 annual report - Canada.ca
- Data on cannabis adverse reactions: 2024 annual report - Open Government Portal
Suggested citation
Health Canada. Summary of cannabis-related side effects: .... Ottawa: Health Canada; .... ...
- Date modified:
- ...